Home　/　News

News

The latest R&D progress and company updates from Regenelead.

Breakthrough Against the “King of Cancers”: Regenelead’s Personalized mRNA Cancer Vaccine Debuts Striking Clinical Data at ASCO

Breakthrough Against the “King of Cancers”: Regenelead’s Personalized mRNA Cancer Vaccine Debuts Striking Clinical Data at ASCO

First clinical data for Regenelead’s personalized cancer vac…

Read more
18

China's First AAV Gene Therapy Product for Radiation-Induced Xerostomia, RGL-185, Completed First Subject Dosing — A Key Step Toward Clinical Translation

On September 17, 2026, RGL-185 Injection, an AAV gene therapy product independently developed by Shanghai Rege…

→
07

Personalized neoantigen mRNA Vaccine RGL-270 receives clinical trial clearance, advancing a new approach to preventing recurrence after solid tumor surgery

Moderna’s personalized neoantigen mRNA vaccine recently achieved positive results in a Phase III trial as adju…

→
09

A Breakthrough in Regenerative Therapy: Innovative mRNA Drug Cleared for Clinical Trials, Opening a New Chapter in Osteoarthritis Regeneration and Repair

On April 1, 2026, RGL-236 for Injection, an mRNA drug jointly developed by Shanghai Regenelead Therapies Co., …

→